Glenmark Share Price Target 2024, 2025, 2027, 2030, 2040

If you think about which share will be best for investment in recent times then you should know about Glenmark Share Price Target. Today in our blog we will explain the basic idea about Glenmark Share Price Target 2024, 2025, 2027, 2030, 2040. We did the research and took advice from experts to make this blog about the company’s growth, performance, etc.

Glenmark Share Price Target is a trading share in the share market. In this article, we will discuss the company’s financial growth, business policy, shareholding pattern, and forecast share price yearly. We use expert data and analysis to understand the Glenmark Share Price Target 2024 to 2040.

What Is Glenmark Pharmaceutical Limited Company?

Glenmark Pharmaceutical Limited Company is an Indian multinational pharmaceutical company that was established in 1977. The company’s headquarters is situated in Mumbai, India. In 1977, the company was established as a generic drug and active pharmaceutical ingredient manufacturer. The Company exports its products to India, Russia, and Africa.

Overview Of Glenmark Pharmaceutical Company

In recent times the company also focused on new drugs and biosimilars in the fields of cancer, dermatology, and respiratory diseases. in the year 2016, the company’s R&D department innovated a drug to treat asthma and COPD and licensed this to North America and Japan. The company also licensed out a diabetes drug to the German.

Financial Data Analysis Of Glenmark Pharmaceutical Company

We need a basic idea about the company’s PE ratio, return on assets, current ratio, and return on equity. In the below portion, we discuss the performance of the company. Glenmark Share Price Target also depended upon the ratio described below.

Also Read – Suven Pharma Share Price Target

History Of Glenmark Share Price Target From 2024 to 2040

Glenmark Share is a bullish trend in the share market. Glenmark Share is under the both Indian Stock Exchange BSE (Bombay Stock Exchange) and NSE (National Stock Exchange). The last 6 month’s share price growth was +539.80 (60.64%), the last 1 year’s share price growth was +641.70 (81.40%), the last 5 year’s share price growth was +1,003.85 (235.56%), and the last maximum year’s share price growth was +1,405.05 (5,631.46%).

Glenmark Share Price return percentage was 37.74% in the last 3 months, the last 1 year’s share price return percentage was 89.32%, the last 3 years’ share price return percentage was 120.12%, and the last 5 years’ share price return percentage was 239.12%. Glenmark Share always gives good returns to investors. If anyone wants to invest in the share it will be profitable on a long-term basis. Let’s have a look at Glenmark Share Price Target from 2024 to 2040.

Glenmark Share Price Target 2024

Glenmark Pharmaceutical Company is designed to cater to both small-volume, high-volume molecules, large and mid-volume molecules. The company has 6 Global Markets in North America, Europe, Japan, Latin America, India, and the rest of the world. The company has 436 DMFs and CEPs across major markets. The company has 26 products in the development pipeline out of which 2 are iron complex and the other 7 are Oncology products.

The Sales Growth of the company was 8.32% in the last 5 years which decreased to 7.01% in the last 3 years and in the last 1 year, the percentage became 0.98%. The Net Sales amount of the company was ₹1,989.23 Crore in March 2023 which increased to ₹2,296.32 Crore in March 2024. If we look at Glenmark Share Price Target 2024 forecast, the 1st Price Target is ₹1,275.41 and the 2nd Price Target is ₹1,685.23.

Glenmark Share Price Target 2025

Glenmark Pharmaceutical Company has a presence in more than 80 countries. The company has 5 manufacturing facilities which are approved by the U.S.FDA, and has 4 R&D Centers. The R&D Centres are situated in Sinnar, Mahape, Taloja & Lausanne. The company also discovers centers in the areas of Dermatology, Oncology, and Respiratory therapy. The Global Revenue of the company is ₹11,848 Crore every year.

The total revenue of Glenmark Pharmaceuticals Company was ₹9,307.23 Crore in March 2023 which decreased to ₹9,059.63 Crore in March 2024. The total operating revenue amount was ₹8,230.45 Crore in March 2023 which decreased to ₹7,891.52 Crore in March 2024. If we look at the Glenmark Share Price Target 2025 forecast, the 1st Price Target is ₹1,712.02 and the 2nd Price Target is ₹1,945.33.

Glenmark Share Price Target 2027

Some of the products manufactured by the company are Dusting Powders like Candid used for fungus, yeast infections, Ascoril Cough Syrup used for runny nose, itching of the throat, Medicated Shampoo (Scalpe Plus) used for itching & flaking of the scale, etc. Some of the brands under this company are Alex-P Syrup, Glinate, Palnox, Vorth-XT, Bortrac, Onabet, Zinox, Fintop, Sibet, Glucar, etc. The company ranked 80 out of 100 World’s top Biopharmaceuticals Companies and 50 Generics & biosimilar companies.

The Profit Growth of the company is not very good. The last 5 years’ Profit Growth percentage was 3.58% which decreased to -3.75% in the last 3 years and in the last 1 year the percentage became -40.12%. The Net Profit amount of the company was ₹1,999.01 Crore in March 2022 which decreased to ₹1,215.23 Crore in March 2023. If we look at the Glenmark Share Price Target 2030 forecast, the 1st Price Target is ₹2,312.52 and the 2nd Price Target is ₹2,645.23.

Also Read – Gland Pharma Share Price Target

Glenmark Share Price Target 2030

The Glenmarkh Company has 10 manufacturing facilities, and 50 local offices situated in over 50 countries. The company has more than 15000 employees on a worldwide basis out of which 1400 employees are attached to the R&D department of the company. In the year 2024, the Glenmark company and its subsidiaries Ichnos Sciences Inc. initiated a collaboration to form Ichnos Glenmark Innovation which comprises 3 oncology molecules focusing on myeloma, acute myeloid leukemia, and solid tumors.

As the company is a very old company and has good market value the promoter holding capacity of the company is also very good which is 46.61% which means many good investor wants to invest in the share. The company also spread its business outside of India the FII investor percentage of the company also increased to 20.99% which is a very good side for the company’s growth. If we look at the Glenmark Share Price Target 2030 forecast, the 1st Price Target is ₹3,312.52 and the 2nd Price Target is ₹3,685.42.

Glenmark Share Price Target 2040

Glenmark Pharmaceutical Company always focuses on the quality of its products. In the year 2020, during the COVID-19 period, the company launched a powerful drug “Favipiravir” under the brand name FabiFlu. In the year 2024, the company introduced an anti-diabetic drug Liraglutide, through this product the company entered into the domain of injectable anti-diabetic therapies. The company also entered into an exclusive licensing agreement with Australia for its nasal spray Ryaltris.

The total expenditure amount of the company was ₹8,142.52 Crore in March 2022 which increased to ₹8,321.02 Crore In March 2023. The ROE percentage of the company was 11.25% in the last 5 years which became 10.23% in the last 3 years and in the last 1 year, the ROE percentage became 6.99%. If we look at the Glenmark Share Price Target 2040 forecast, the 1st Price Target is ₹7,414.45 and the 2nd Price Target is ₹7,785.63.

Peer’s Company of Glenmark Pharmaceuticals Company

• Aarey Drugs
• Aarti Drugs
• Abbott India
• Advanced Enzyme
• Advik Labors

Investors Types And Ratio Of Glenmark Pharmaceuticals Company

There are mainly four main Types of Investors in Glenmark Pharmaceuticals Company. The company’s growth also depended upon the ratio of investors who invested in the share.

Promoters Holding

Promoters Holding means how much capital is invested by company promoters (owner of the company) through overall capital. Glenmark Pharmaceuticals Company’s promoter holding capacity is 46.61%.

Public Holding

Public Investors are individuals who invest in the public market for profit in the future (large and small companies). Glenmark Pharmaceuticals Company’s public holding capacity is 18.42%.

FII

Foreign Institutional Investors are those big companies that invest in different countries company. Glenmark Pharmaceuticals Company’s FII is 20.99%.

DII

Domestic Institutional Investors (like Insurance, companies mutual funds) who invest in their own country. Glenmark Pharmaceuticals Company’s DII is 13.98%.

Advantages and Disadvantages Of Glenmark Pharmaceuticals Share

Every share has some advantages and some disadvantages also. So, the Glenmark Pharmaceuticals Share Price Target also has some advantages and disadvantages.

Advantages

• The Company has an efficient cash conversation cycle of -77.75 days.
• The Company has good cash flow management, PAT stands at 1.05.
• The company has a small amount of debt and the interest cover ratio of the company is also very good which is 8.61.
• The FII investor percentage of the company increased to 20.99%.

Disadvantages

• The net profit growth of the company decreased in the last 3 years which is 3.58% in the last 3 years.
• The revenue growth of the company decreased to 6.99% in the last 3 years.
• The ROA percentage of the company decreased in the last 2 years.
• The net cash flow amount of the company decreased.

Also Read – Sun Pharma Share Price Target

FAQ

Conclusion

Hopefully, www.sharetargethub.com will help you gain some basic ideas about the Glemark Share Price Target. By doing the research and taking advice from expertise we ensure that on a long-term basis, Glemark Share Price Target may reach a very high position. Glemark Company is related to the pharmaceutical Sector. So the demand for this sector also increases which helps the share to gain profit in the future.

If you think this website will be helpful for you then you can share it. If you have any questions please let us know through the comment box we will try to reply to your questions and solve your problem. Thanks for visiting this website and thanks for being with us.

Disclaimer – We are not SEBI-registered advisors. A financial market is always risky to anyone. This website is only for training and educational purposes. So before investing, we are requested to discuss certified expertise. We will not be responsible for anyone’s profit or loss.